Chemistry — US PTAB Patent Cases
3 decisions indexed
Page 1 of 1 · 3 total
Entegris, Inc. v.Inpria Corporation
Entegris has filed an IPR petition seeking cancellation of claims 1‑4 and 6‑10 of Inpria’s ’903 patent, asserting that the claimed high‑purity organotin compositions are fully disclosed in earlier literature. The petition challenges the patent on anticipation and obviousness grounds and argues that Inpria’s examiner‑era declarations were misleading.
Clean Chemistry, Inc. v.Enviro Tech Chemical Services, Inc. et al.
Clean Chemistry has filed an IPR petition seeking to invalidate all 14 claims of Enviro Tech’s peracetic acid patent, arguing obviousness over Okano and combinations with Withenshaw and Oringer. The petition also asserts that the claims require steps to be performed in order.
LCY Biotechnology Holding, Inc. v.Radici Chimica, S.p.A.
LCY Biotechnology and Radici Chimica settled their post‑grant review dispute over U.S. Patent 11,781,148. The parties filed a joint motion to terminate, and the PTAB dismissed the petition, terminating the proceeding.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.